Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation’s Health and Prosperity
Tevogen Bio (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, addressed concerns about short-selling impacts on healthcare innovation. CEO Dr. Ryan Saadi highlighted the company's progress since going public, including a notable collaboration between Tevogen.AI and Microsoft to explore AI applications in biotechnology.
Despite these developments, the company's share price has experienced pressure. The statement emphasizes how short-selling activities could divert biotech executives' attention from core priorities like patient accessibility and national security initiatives. The company reaffirmed its commitment to developing accessible and affordable precision medicine while advocating for market transparency.
Tevogen Bio (Nasdaq: TVGN), una società biotech specializzata in immunoterapia in fase clinica, ha affrontato le preoccupazioni riguardanti l'impatto delle vendite allo scoperto sull'innovazione nel settore sanitario. Il CEO Dr. Ryan Saadi ha messo in evidenza i progressi dell'azienda dalla sua quotazione in borsa, inclusa una collaborazione significativa tra Tevogen.AI e Microsoft per esplorare le applicazioni dell'IA nella biotecnologia.
Nonostante questi sviluppi, il prezzo delle azioni dell'azienda ha subito delle pressioni. La dichiarazione sottolinea come le attività di vendita allo scoperto possano distogliere l'attenzione dei dirigenti biotech da priorità fondamentali come l'accessibilità per i pazienti e le iniziative di sicurezza nazionale. L'azienda ha ribadito il suo impegno nello sviluppo di medicine di precisione accessibili e abbordabili, sostenendo al contempo la trasparenza del mercato.
Tevogen Bio (Nasdaq: TVGN), una empresa biotecnológica especializada en inmunoterapia en etapa clínica, abordó las preocupaciones sobre el impacto de las ventas en corto en la innovación en salud. El CEO Dr. Ryan Saadi destacó el progreso de la empresa desde su salida a bolsa, incluida una colaboración notable entre Tevogen.AI y Microsoft para explorar aplicaciones de IA en biotecnología.
A pesar de estos desarrollos, el precio de las acciones de la empresa ha experimentado presión. La declaración enfatiza cómo las actividades de ventas en corto podrían desviar la atención de los ejecutivos de biotecnología de prioridades fundamentales como la accesibilidad para los pacientes y las iniciativas de seguridad nacional. La empresa reafirmó su compromiso de desarrollar medicina de precisión accesible y asequible, al tiempo que aboga por la transparencia del mercado.
Tevogen Bio (Nasdaq: TVGN)은 임상 단계의 전문 면역 요법 생명공학 회사로서 헬스케어 혁신에 대한 공매도 영향에 대한 우려를 다뤘습니다. CEO인 Dr. Ryan Saadi는 상장 이후 회사의 발전을 강조하며, Tevogen.AI와 Microsoft 간의 협력이 생명공학에서 AI 응용을 탐색하기 위해 이루어졌다고 밝혔습니다.
이러한 발전에도 불구하고 회사의 주가는 압박을 받았습니다. 이 성명서는 공매도 활동이 생명공학 경영진의 환자 접근성과 국가 안전 보장 이니셔티브와 같은 핵심 우선사항에서 주의를 분산시킬 수 있음을 강조합니다. 회사는 접근 가능하고 저렴한 정밀 의학을 개발하겠다는 의지를 재확인하며 시장 투명성을 옹호했습니다.
Tevogen Bio (Nasdaq: TVGN), une entreprise biopharmaceutique spécialisée en immunothérapie en phase clinique, a abordé les préoccupations concernant l'impact des ventes à découvert sur l'innovation en santé. Le PDG Dr. Ryan Saadi a souligné les progrès de l'entreprise depuis son introduction en bourse, y compris une collaboration notable entre Tevogen.AI et Microsoft pour explorer les applications de l'IA en biotechnologie.
Malgré ces développements, le prix des actions de l'entreprise a subi des pressions. La déclaration souligne comment les activités de vente à découvert pourraient détourner l'attention des dirigeants de biotechnologie des priorités essentielles telles que l'accessibilité pour les patients et les initiatives de sécurité nationale. L'entreprise a réaffirmé son engagement à développer des médicaments de précision accessibles et abordables tout en plaidant pour la transparence du marché.
Tevogen Bio (Nasdaq: TVGN), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat Bedenken hinsichtlich der Auswirkungen von Leerverkäufen auf Innovationen im Gesundheitswesen geäußert. CEO Dr. Ryan Saadi hob die Fortschritte des Unternehmens seit dem Börsengang hervor, einschließlich einer bemerkenswerten Zusammenarbeit zwischen Tevogen.AI und Microsoft, um KI-Anwendungen in der Biotechnologie zu erkunden.
Trotz dieser Entwicklungen hat der Aktienkurs des Unternehmens Druck erfahren. Die Erklärung betont, wie Leerverkaufsaktivitäten die Aufmerksamkeit von Biotech-Führungskräften von wichtigen Prioritäten wie der Patientenversorgung und nationalen Sicherheitsinitiativen ablenken könnten. Das Unternehmen bekräftigte sein Engagement für die Entwicklung von zugänglicher und erschwinglicher Präzisionsmedizin und plädiert für Markttransparenz.
- Strategic partnership with Microsoft for AI applications in biotechnology
- Share price under pressure from short-selling activities
WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, today issued a statement from its Founder and CEO, Nobel Peace Prize nominee Dr. Ryan Saadi, regarding broader implications of short-selling.
“Tevogen Bio is committed to advancing innovative medical solutions while maintaining affordability for patients, a mission that is essential for sustainable healthcare innovation. Since going public, we have made significant progress, including a collaboration between Tevogen.AI and Microsoft (Nasdaq: MSFT) to explore AI applications in biotechnology. Despite these advancements, our share price has faced pressure,” said Dr. Ryan Saadi, Founder & CEO of Tevogen Bio.
“This brings into question the indirect impact of short-selling on healthcare innovation, where executives of emerging biopharma companies might divert attention to defending against short attacks rather than focusing on critical priorities like patient accessibility, national security initiatives, and supporting President Trump and Secretary Kennedy’s efforts to strengthen our healthcare system,” Dr. Saadi added.
William Keane, Vice President of Strategic Initiatives, commented, “As we continue advancing our pipeline, we remain committed to delivering long-term value for patients and shareholders. Retail investors, everyday Americans who fuel public markets, deserve transparency and fairness.”
Tevogen Bio remains steadfast in its mission to pioneer accessible and affordable precision medicine while advocating for fair and transparent market participation.
About Tevogen Bio
Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies to treat infectious disease and cancers, aiming to address the significant unmet needs of large patient populations. Tevogen Bio leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen Bio has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.
Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen Bio’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: expectations regarding the healthcare and biopharmaceutical industries; Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer; Tevogen’s plans to expand its efforts in artificial intelligence; Tevogen’s ability to develop additional product candidates; Tevogen’s use of funds from the grant; and the potential receipt of additional future grants. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the effect of the recent business combination with Semper Paratus Acquisition Corporation (the “Business Combination”) on Tevogen’s business relationships, operating results, and business generally; the outcome of any legal proceedings that may be instituted against Tevogen; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; costs related to the Business Combination and the failure to realize anticipated benefits of the Business Combination; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; the ability to develop, license or acquire new therapeutics; that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K and subsequent filings with the SEC.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
FAQ
What is the partnership between Tevogen Bio (TVGNW) and Microsoft about?
How is short-selling affecting Tevogen Bio's (TVGNW) stock performance?
What is Tevogen Bio's (TVGNW) current business focus?
What measures is Tevogen Bio (TVGNW) taking to address short-selling pressure?
